Surain B Roberts,Woo Jin Choi,Lawrence Worobetz,Catherine Vincent,Jennifer A Flemming,Angela Cheung,Karim Qumosani,Mark Swain,Dusanka Grbic,Hin Hin Ko,Kevork M Peltekian,Lusine Abrahamyan,Monika Saini,Kattleya Tirona,Bishoi Aziz,Ellina Lytvyak,Pietro Invernizzi,Cyriel Y Ponsioen,Tony Bruns,Nora Cazzagon,Keith Lindor,George N Dalekos,Nikolaos K Gatselis,Xavier Verhelst,Annarosa Floreani,Christophe Corpechot,Marlyn J Mayo,Cynthia Levy,Maria-Carlota Londoño,Pier M Battezzati,Albert Pares,Frederik Nevens,Adriaan van der Meer,Kris V Kowdley,Palak J Trivedi,Ana Lleo,Douglas Thorburn,Marco Carbone,Nazia Selzner,Aliya F Gulamhusein,Harry LA Janssen,Aldo J Montano-Loza,Andrew L Mason,Gideon M Hirschfield,Bettina E Hansen,Canadian Network for Autoimmune Liver disease (CaNAL)

Abstract:Background & aims: Biochemical response to ursodeoxycholic acid (UDCA) therapy is associated with good prognosis in people living with primary biliary cholangitis (PBC). Biochemical response is typically assessed early in disease and it is not known what proportion of patients lose previously attained biochemical response, nor whether this impacts long-term liver transplant (LT)-free survival. Methods: We identified all UDCA-treated patients with PBC from the Canadian Network for Autoimmune Liver disease with biochemical measurements at 1 year, and evaluated their liver biochemistry over time. Inadequate biochemical response was defined as serum alkaline phosphatase ≥1.67x the upper limit of normal or abnormal serum total bilirubin at 1 year of UDCA therapy and all time points thereafter. Multistate Markov models were used to estimate transition rates between biochemical response states and from each state to LT or death. Results were validated in an external cohort (GLOBAL PBC registry). Results: A total of 823 patients from eight centers were included. Mean age at diagnosis was 53 years, 91% were female, 33% had inadequate biochemical response to UDCA at 1 year (n = 269). Patients who retained initial adequate response had lower rates of LT or death compared to patients who subsequently lost response (relative rate 0.102, 95% CI 0.047-0.223). Patients who regained adequate response had lower rates than patients who did not (0.016, 95% CI 0.001-0.568), and patients who lost response once more (0.010, 95% CI 0.001-0.340). Patients who regained adequate response for a third time also had lower rates than patients who did not (0.151, 95% CI 0.040-0.566). Analyses in the GLOBAL PBC registry (n = 2,237) validated these results. Conclusion: Loss of biochemical response at any time is associated with heightened risks of LT or death in people living with PBC. Achievement of biochemical response is an important goal throughout follow-up, regardless of biochemical response profile early in therapy. Impact and implications: Early biochemical response to ursodeoxycholic acid is associated with good prognosis in patients with primary biliary cholangitis (PBC). Our work demonstrates that patients with PBC transition between biochemical response states over time, and that these transitions correspond with changes in risk of liver transplantation or death. Clinicians should re-evaluate risk and optimize treatment decisions for patients with PBC throughout follow-up, regardless of early biochemical response to therapy.

Longitudinal outcomes of obeticholic acid therapy in ursodiol‐nonresponsive primary biliary cholangitis: Stratifying the impact of add‐on fibrates in real‐world practice

Obeticholic Acid—A Pharmacological and Clinical Review

Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study

Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy

Response to Ursodeoxycholic Acid May Be Assessed Earlier to Allow Second-Line Therapy in Patients with Unresponsive Primary Biliary Cholangitis

Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one‐year non‐responders and predicts survival

Biochemical response to obeticholic acid drives liver stiffness variation over time and the risk of liver-related events in patients with primary biliary cholangitis

Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis

Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials.

A new and simple score to predict adequate and deep response to ursodeoxycholic acid in patients with primary biliary cholangitis: the ALP-A score

Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid

Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis

A Two-Year Follow-Up Study on the Efficacy of Ursodeoxycholic Acid on Primary Biliary Cirrhosis in Different Stages

Obeticholic acid for the treatment of primary biliary cirrhosis

Fenofibrate Normalizes Alkaline Phosphatase and Improves Long-Term Outcomes in Patients with Advanced Primary Biliary Cholangitis Refractory to Ursodeoxycholic Acid

Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to 28 Years

A Multicenter, Randomized, Double-Blind Trial Comparing The Efficacy And Safety Of Tudca And Udca In Chinese Patients With Primary Biliary Cholangitis

Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy

Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?

Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators

Up-to-Date Snapshot of Current and Emerging Medical Therapies in Primary Biliary Cholangitis